共 4 条
[2]
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women[J] . J Paavonen,P Naud,J Salmerón,CM Wheeler,S-N Chow,D Apter,H Kitchener,X Castellsague,JC Teixeira,SR Skinner,J Hedrick,U Jaisamrarn,G Limson,S Garland,A Szarewski,B Romanowski,FY Aoki,TF Schwarz,WAJ Poppe,FX Bosch,D Jenkins,K Hardt,T Zahaf,D Descamps,F Struyf,M Lehtinen,G Dubin.
[3]
Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008[J] . Anna Koulova,Jennifer Tsui,Kathleen Irwin,Pierre Van Damme,Robin Biellik,Maria Teresa Aguado.Vaccine . 2008 (51)
[4]
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial[J] . Jorma Paavonen,David Jenkins,F Xavier Bosch,Paulo Naud,Jorge Salmerón,Cosette M Wheeler,Song-Nan Chow,Dan L Apter,Henry C Kitchener,Xavier Castellsague,Newton S de Carvalho,S Rachel Skinner,Diane M Harper,James A Hedrick,Unnop Jaisamrarn,Genara AM Limson,Marc Dion